KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aquestive Therapeutics (AQST) Research & Development (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Research & Development data on record, last reported at $3.2 million in Q4 2025.

  • For Q4 2025, Research & Development fell 35.0% year-over-year to $3.2 million; the TTM value through Dec 2025 reached $17.2 million, down 15.23%, while the annual FY2025 figure was $17.2 million, 15.23% down from the prior year.
  • Research & Development reached $3.2 million in Q4 2025 per AQST's latest filing, down from $4.5 million in the prior quarter.
  • Across five years, Research & Development topped out at $5.9 million in Q1 2024 and bottomed at $2.9 million in Q4 2023.
  • Average Research & Development over 5 years is $4.3 million, with a median of $4.3 million recorded in 2021.
  • Peak YoY movement for Research & Development: skyrocketed 70.26% in 2024, then plummeted 35.0% in 2025.
  • A 5-year view of Research & Development shows it stood at $4.4 million in 2021, then decreased by 2.77% to $4.3 million in 2022, then crashed by 32.49% to $2.9 million in 2023, then soared by 70.26% to $4.9 million in 2024, then tumbled by 35.0% to $3.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $3.2 million in Q4 2025, $4.5 million in Q3 2025, and $4.1 million in Q2 2025.